Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 06, 2005. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the company. It does not contain a general business overview or operational results.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share transaction prices and volumes within employee benefit plans:
- US Retirement Savings Plan (June 30, 2005): Average price of $49.15 per ADR.
- US Retirement Savings Plan (July 1, 2005): Average price of $48.51 per ADR.
- SmithKline Beecham Bonus Investment Plan (June 27, 2005): Sale price of £13.2925 per share.
- Notional Investment Re-valuation (July 1, 2005): Price of $48.24 per share.
Material Changes
The filing details changes in shareholdings within specific employee trusts and plans rather than corporate financial performance:
- US Retirement Savings Plan: Holdings decreased from 18,314,545 to 18,298,991 ADRs on June 30, then increased to 18,354,038 ADRs on July 1.
- GSK Employee Trust: 920 Ordinary Shares were transferred to participants in the SmithKline Beecham Employee Share Option Plan 1991 on July 1.
- Bonus Investment Plan: 7,310 shares were sold and 10,389 shares were transferred to a participant on June 27.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is strictly a regulatory disclosure of director and connected person transactions under Disclosure Rule 3.1.4R(1)(b) and 3.1.4R(1)(a).
Key Facts for Investor Verification
- Verify the impact of the reported share movements on the total outstanding share count, noting these are internal trust transactions.
- Confirm the identities of directors with potential interests in the funds: Dr J P Garnier, Dr T Yamada, and Mr J S Heslop.
- Note that the reported share prices ($48.24 - $49.15 and £13.2925) reflect specific transaction dates in late June and early July 2005, not necessarily the closing market price for the period.
- Understand that this filing does not replace or summarize quarterly or annual financial results.